Terpenoids as potential chemopreventive and therapeutic agents in liver cancer

World Journal of Hepatology

Volumn 3, Issue 9, 2011, Pages 228-249

  Thoppil, Roslin J ^a   Bishayee, Anupam ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeastern Ohio Medical University   (United States)

Author keywords

Apoptosis; Cell cycle; Chemoprevention; Hepatocarcinogenesis; Hepatocellular carcinoma; Liver cancer cells; Terpenoids; Treatment

Indexed keywords

EID: 84861024238     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v3.i9.228     Document Type: Review

References (194)

1. Nakashima T, Okuda K, Kojiro M, Jimi A, Yamaguchi R, Sakamoto K, Ikari T. Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer 1983; 51: 863-877
2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16
3. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259
4. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-154
5. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34
6. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
7. Raoul JL. Natural history of hepatocellular carcinoma and current treatment options. Semin Nucl Med 2008; 38: S13-S18
8. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92
9. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917
10. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-524
11. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-1229
12. Sato S, Shiratori Y, Imamura M, Teratani T, Obi S, Koike Y, Imai Y, Yoshida H, Shiina S, Omata M. Power Doppler signals after percutaneous ethanol injection therapy for hepatocellular carcinoma predict local recurrence of tumors: a prospective study using 199 consecutive patients. J Hepatol 2001; 35: 225-234
13. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807
14. Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, Curley SA, Pollock RE, Vauthey JN. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 2002; 235: 722-730; discussion 730-731
15. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086
16. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403
17. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-235
18. Lencioni R, Pinto F, Armillotta N, Bassi AM, Moretti M, Di Giulio M, Marchi S, Uliana M, Della Capanna S, Lencioni M, Bartolozzi C. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7: 514-519
19. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002; 99: 15584-15589
20. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, MoscoviciM, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
22. Lu SC. Where are we in the chemoprevention of hepatocellular carcinoma? Hepatology 2010; 51: 734-736
23. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and metaanalysis of clinical trials. Lancet Oncol 2009; 10: 967-974
24. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 525-530
25. Jordan VC. Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev Cancer 2007; 7: 46-53
26. Castrellon AB, Glück S. Chemoprevention of breast cancer. Expert Rev Anticancer Ther 2008; 8: 443-452
27. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006; 71: 1397-1421
28. Russo GL. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem Pharmacol 2007; 74: 533-544
29. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG. Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 2008; 15: 1044-1071
30. Kaefer CM, Milner JA. The role of herbs and spices in cancer prevention. J Nutr Biochem 2008; 19: 347-361
31. Moiseeva EP, Manson MM. Dietary chemopreventive phytochemicals: too little or too much?. Cancer Prev Res (Phila) 2009; 2: 611-616
32. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer 2010 ; 62: 1-20
33. Bishayee A, Darvesh AS. Oxidative stress in cancer and neurodegenrative diseases: prevention and treatment by dietary antioxidants. In: Kozyrev D, Slutsky V, editors. Free radicals: formation, types and effects. Hauppauge, NY: Nova Science Publishers, 2010: 1-55
34. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, Griel AE, Etherton TD. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 2002; 113 Suppl 9B: 71S-88S
35. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003; 78: 559S-569S
36. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR, 2007
37. Nishino H. Phytochemicals in hepatocellular cancer prevention. Nutr Cancer 2009; 61: 789-791
38. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 2009; 18: 13-25
39. Glauert HP, Calfee-Mason K, Stemm DN, Tharappel JC, Spear BT. Dietary antioxidants in the prevention of hepatocarcinogenesis: a review. Mol Nutr Food Res 2010; 54: 875-896
40. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010; 36: 43-53
41. Darvesh AS, Aggarwal BB, Bishayee A. Curcumin and Liver Cancer: A Review. Curr Pharm Biotechnol 2011; Epub ahead of print
42. Sacchettini JC, Poulter CD. Creating isoprenoid diversity. Science 1997; 277: 1788-1789
43. Peñuelas J, Munné-Bosch S. Isoprenoids: an evolutionary pool for photoprotection. Trends Plant Sci 2005; 10: 166-169
44. Withers ST, Keasling JD. Biosynthesis and engineering of isoprenoid small molecules. Appl Microbiol Biotechnol 2007; 73: 980-990
45. Rabi T, Bishayee A. Terpenoids and breast cancer chemoprevention. Breast Cancer Res Treat 2009; 115: 223-239
46. Wagner KH, Elmadfa I. Biological relevance of terpenoids. Overview focusing on mono-, di- and tetraterpenes. Ann Nutr Metab 2003; 47: 95-106
47. Sultana N, Ata A. Oleanolic acid and related derivatives as medicinally important compounds. J Enzyme Inhib Med Chem 2008; 23: 739-756
48. Shah BA, Qazi GN, Taneja SC. Boswellic acids: a group of medicinally important compounds. Nat Prod Rep 2009; 26: 72-89
49. Theis N, Lerdau M. The evolution of function in plant secondary metabolites. Int J Plant Sci 2003; 164: S93-S103
50. Gould MN. Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 1997; 105 Suppl 4: 977-979
51. Reddy BS, Wang CX, Samaha H, Lubet R, Steele VE, Kelloff GJ, Rao CV. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 1997; 57: 420-425
52. Vigushin DM, Poon GK, Boddy A, English J, Halbert GW, Pagonis C, Jarman M, Coombes RC. Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol 1998; 42: 111-117
53. Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999; 129: 775S-778S
54. Burke YD, Ayoubi AS, Werner SR, McFarland BC, Heilman DK, Ruggeri BA, Crowell PL. Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res 2002; 22: 3127-3134
55. de Carvalho CCCR, da Fonseca MMR. Carvone: Why and how should one bother to produce this terpene. Food Chem 2006; 95: 413-422
56. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007; 7: 357-369
57. Setzer WN, Setzer MC. Plant-derived triterpenoids as potential antineoplastic agents. Mini Rev Med Chem 2003; 3: 540-556
58. Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med 2009; 75: 1549-1560
59. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009; 20: 880-892
60. Chaturvedi PK, Bhui K, Shukla Y. Lupeol: connotations for chemoprevention. Cancer Lett 2008; 263: 1-13
61. Rabi T, Gupta S. Dietary terpenoids and prostate cancer chemoprevention. Front Biosci 2008; 13: 3457-3469
62. Mullauer FB, Kessler JH, Medema JP. Betulinic acid, a natural compound with potent anticancer effects. Anticancer Drugs 2010; 21: 215-227
63. Bishayee A, Ahmed S, Brankov N, Perloff M. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 2011; 16: 980-996
64. Patlolla JM, Rao CV. Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects. Curr Pharm Biotechnol 2011; Epub ahead of print
65. Liu J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 2005; 100: 92-94
66. Ovesná Z, Vachálková A, Horváthová K, Tóthová D. Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma 2004; 51: 327-333
67. Fulda S. Betulinic acid: a natural product with anticancer activity. Mol Nutr Food Res 2009; 53: 140-146
68. Polo MP, de Bravo MG. Effect of geraniol on fatty-acid and mevalonate metabolism in the human hepatoma cell line Hep G2. Biochem Cell Biol 2006; 84: 102-111
69. Ji L, Liu T, Liu J, Chen Y, Wang Z. Andrographolide inhibits human hepatoma-derived Hep3B cell growth through theactivation of c-Jun N-terminal kinase. Planta Med 2007; 73: 1397-1401
70. Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, Zhu XF. ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther 2009; 8: 873-882
71. Yoshida M, Matsui Y, Iizuka A, Ikarashi Y. G2-phase arrest through p21( WAF1 / Cip1) induction and cdc2 repression by gnidimacrin in human hepatoma HLE cells. Anticancer Res 2009; 29: 1349-1354
72. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK, and mitochondrial signaling pathways. J Pharmacol Sci 2008; 107: 370-379
73. Rebbeck TR, Troxel AB, Norman S, Bunin GR, DeMichele A, Baumgarten M, Berlin M, Schinnar R, Strom BL. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int J Cancer 2007; 120: 1523-1528
74. Zepelin HH, Meden H, Kostev K, Schröder-Bernhardi D, Stammwitz U, Becher H. Isopropanolic black cohosh extract and recurrence-free survival after breast cancer. Int J Clin Pharmacol Ther 2007; 45: 143-154
75. Einbond LS, Soffritti M, Esposti DD, Park T, Cruz E, Su T, Wu HA, Wang X, Zhang YJ, Ham J, Goldberg IJ, Kronenberg F, Vladimirova A. Actein activates stress- and statin-associated responses and is bioavailable in Sprague-Dawley rats. Fundam Clin Pharmacol 2009; 23: 311-321
76. Li M, Wei SY, Xu B, Guo W, Liu DL, Cui JR, Yao XS. Proapoptotic and microtubule-disassembly effects of ardisiacrispin (A+B), triterpenoid saponins from Ardisia crenata on human hepatoma Bel- 7402 cells. J Asian Nat Prod Res 2008; 10: 739-746
77. Wang GL, Chen CB, Gao JM, Ni H, Wang TS, Chen L. [Investigation on the molecular mechanisms of anti-hepatocarcinoma herbs of traditional Chinese medicine by cell cycle microarray]. Zhongguo Zhongyao Zazhi 2005; 30: 50-54
78. Qi H, Wei L, Han Y, Zhang Q, Lau AS, Rong J. Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2. Int J Oncol 2010; 36: 725-735
79. Lee YS, Jin DQ, Kwon EJ, Park SH, Lee ES, Jeong TC, Nam DH, Huh K, Kim JA. Asiatic acid, a triterpene, induces apoptosis through intracellular Ca2+ release and enhanced expression of p53 in HepG2 human hepatoma cells. Cancer Lett 2002; 186: 83-91
80. Eichenmüller M, von Schweinitz D, Kappler R. Betulinic acid treatment promotes apoptosis in hepatoblastoma cells. Int J Oncol 2009; 35: 873-879
81. Ruizi Altaba A, Sánchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002; 2: 361-372
82. Evangelista M, Tian H, de Sauvage FJ. The hedgehog signaling pathway in cancer. Clin Cancer Res 2006; 12: 5924-5928
83. Zhang M, Zhang H, Sun C, Shan X, Yang X, Li-Ling J, Deng Y. Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother Pharmacol 2009; 63: 635-642
84. Chan KT, Meng FY, Li Q, Ho CY, Lam TS, To Y, Lee WH, Li M, Chu KH, Toh M. Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL- 7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010; 294: 118-124
85. Takahashi N, Yoshida Y, Sugiura T, Matsuno K, Fujino A, Yamashita U. Cucurbitacin D isolated from Trichosanthes kirilowii induces apoptosis in human hepatocellular carcinoma cells in vitro. Int Immunopharmacol 2009; 9: 508-513
86. Meng D, Qiang S, Lou L, Zhao W. Cytotoxic cucurbitanetype triterpenoids from Elaeocarpus hainanensis. Planta Med 2008; 74: 1741-1744
87. Tong X, Lin S, Fujii M, Hou DX. Molecular mechanisms of echinocystic acid-induced apoptosis in HepG2 cells. Biochem Biophys Res Commun 2004; 321: 539-546
88. Zhou XY, Fu FH, Li Z, Dong QJ, He J, Wang CH. Escin, a natural mixture of triterpene saponins, exhibits antitumor activity against hepatocellular carcinoma. Planta Med 2009; 75: 1580-1585
89. Yang HL. Ganoderic acid produced from submerged culture of Ganoderma lucidum induces cell cycle arrest and cytotoxicity in human hepatoma cell line BEL7402. Biotechnol Lett 2005; 27: 835-838
90. Chang UM, Li CH, Lin LI, Huang CP, Kan LS, Lin SB. Ganoderiol F, a ganoderma triterpene, induces senescence in hepatoma HepG2 cells. Life Sci 2006; 79: 1129-1139
91. Lee KY, Lee SK. Ginsenoside-Rg1 positively regulates cyclin E-dependent kinase activity in human hepatoma SK-HEP-1 cells. Biochem Mol Biol Int 1996; 39: 539-546
92. Lee KY, Lee YH, Kim SI, Park JH, Lee SK. Ginsenoside-Rg5 suppresses cyclin E-dependent protein kinase activity via up-regulating p21Cip/ WAF1 and down-regulating cyclin E in SK-HEP- 1 cells. Anticancer Res 1997; 17: 1067-1072
93. Lee KY, Park JA, Chung E, Lee YH, Kim SI, Lee SK. Ginsenoside-Rh2 blocks the cell cycle of SK-HEP-1 cells at the G1/S boundary by selectively inducing the protein expression of p27kip1. Cancer Lett 1996; 110: 193-200
94. Park JA, Lee KY, Oh YJ, Kim KW, Lee SK. Activation of caspase-3 protease via a Bcl-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis. Cancer Lett 1997; 121: 73-81
95. Kim YJ, Kwon HC, Ko H, Park JH, Kim HY, Yoo JH, Yang HO. Anti-tumor activity of the ginsenoside Rk1 in human hepatocellular carcinoma cells through inhibition of telomerase activity and induction of apoptosis. Biol Pharm Bull 2008; 31: 826-830
96. Ko H, Kim YJ, Park JS, Park JH, Yang HO. Autophagy inhibition enhances apoptosis induced by ginsenoside Rk1 in hepatocellular carcinoma cells. Biosci Biotechnol Biochem 2009; 73: 2183-2189
97. Kim SE, Lee YH, Park JH, Lee SK. Ginsenoside-Rs3, a new diol-type ginseng saponin, selectively elevates protein levels of p53 and p21WAF1 leading to induction of apoptosis in SK-HEP- 1 cells. Anticancer Res 1999; 19: 487-491
98. Wang QF, Chen JC, Hsieh SJ, Cheng CC, Hsu SL. Regulation of Bcl- 2 family molecules and activation of caspase cascade involved in gypenosides-induced apoptosis in human hepatoma cells. Cancer Lett 2002; 183: 169-178
99. Oh SH, Lee BH. A ginseng saponin metabolite-induced apoptosis in HepG2 cells involves a mitochondria-mediated pathway and its downstream caspase- 8 activation and Bid cleavage. Toxicol Appl Pharmacol 2004; 194: 221-229
100. Ming YL, Song G, Chen LH, Zheng ZZ, Chen ZY, Ouyang GL, Tong QX. Anti-proliferation and apoptosis induced by a novel intestinal metabolite of ginseng saponin in human hepatocellular carcinoma cells. Cell Biol Int 2007; 31: 1265-1273
101. Tian Z, Liu YM, Chen SB, Yang JS, Xiao PG, Wang L, Wu E. Cytotoxicity of two triterpenoids from Nigella glandulifera. Molecules 2006; 11: 693-699
102. Liu JJ, Nilsson A, Oredsson S, Badmaev V, Duan RD. Ketoand acetyl-keto-boswellic acids inhibit proliferation and induce apoptosis in Hep G2 cells via a caspase-8 dependent pathway. Int J Mol Med 2002; 10: 501-505
103. Weng CJ, Chau CF, Chen KD, Chen DH, Yen GC. The antiinvasive effect of lucidenic acids isolated from a new Ganoderma lucidum strain. Mol Nutr Food Res 2007; 51: 1472-1477
104. Weng CJ, Chau CF, Hsieh YS, Yang SF, Yen GC. Lucidenic acid inhibits PMA-induced invasion of human hepatoma cells through inactivating MAPK/ERK signal transductionpathway and reducing binding activities of NF-kappaB and AP-1. Carcinogenesis 2008; 29: 147-156
105. Zhang L, Zhang Y, Zhang L, Yang X, Lv Z. Lupeol, a dietary triterpene, inhibited growth, and induced apoptosis through down-regulation of DR3 in SMMC7721 cells. Cancer Invest 2009; 27: 163-170
106. Hong J, Min HY, Xu GH, Lee JG, Lee SH, Kim YS, Kang SS, Lee SK. Growth inhibition and G1 cell cycle arrest mediated by 25-methoxyhispidol A, a novel triterpenoid, isolated from the fruit of Poncirus trifoliata in human hepatocellular carcinoma cells. Planta Med 2008; 74: 151-155
107. Yan SL, Huang CY, Wu ST, Yin MC. Oleanolic acid and ursolic acid induce apoptosis in four human liver cancer cell lines. Toxicol In Vitro 2010; 24: 842-848
108. Shyu MH, Kao TC, Yen GC. Oleanolic acid and ursolic acid induce apoptosis in HuH7 human hepatocellular carcinoma cells through a mitochondrial-dependent pathway and downregulation of XIAP. J Agric Food Chem 2010; 58: 6110-6118
109. Tian Z, Lin G, Zheng RX, Huang F, Yang MS, Xiao PG. Antihepatoma activity and mechanism of ursolic acid and its derivatives isolated from Aralia decaisneana. World J Gastroenterol 2006; 12: 874-879
110. Tang C, Lu YH, Xie JH, Wang F, Zou JN, Yang JS, Xing YY, Xi T. Downregulation of survivin and activation of caspase-3 through the PI3K/Akt pathway in ursolic acid-induced HepG2 cell apoptosis. Anticancer Drugs 2009; 20: 249-258
111. Zhang Z, Wang S, Qiu H, Duan C, Ding K, Wang Z. Waltonitone induces human hepatocellular carcinoma cells apoptosis in vitro and in vivo. Cancer Lett 2009; 286: 223-231
112. Wang Y, Zhang D, Ye W, Yin Z, Fung KP, Zhao S, Yao X. Triterpenoid saponins from Androsace umbellata and their anti-proliferative activities in human hepatoma cells. Planta Med 2008; 74: 1280-1284
113. Huang J, Tang XH, Ikejima T, Sun XJ, Wang XB, Xi RG, Wu LJ. A new triterpenoid from Panax ginseng exhibits cytotoxicity through p53 and the caspase signaling pathway in the HepG2 cell line. Arch Pharm Res 2008; 31: 323-329
114. Kozuki Y, Miura Y, Yagasaki K. Inhibitory effects of carotenoids on the invasion of rat ascites hepatoma cells in culture. Cancer Lett 2000; 151: 111-115
115. Huang CS, Shih MK, Chuang CH, Hu ML. Lycopene inhibits cell migration and invasion and upregulates Nm23- H1 in a highly invasive hepatocarcinoma, SK-Hep- 1 cells. J Nutr 2005; 135: 2119-2123
116. Wójcik M, Bobowiec R, Martelli F. Effect of carotenoids on in vitro proliferation and differentiation of oval cells during neoplastic and non-neoplastic liver injuries in rats. J Physiol Pharmacol 2008; 59 Suppl 2: 203-213
117. Yurtcu E, Iseri OD, Sahin FI. Effects of ascorbic acid and β-carotene on HepG2 human hepatocellular carcinoma cell line. Mol Biol Rep 2011; 38: 4265-4272
118. Das SK, Hashimoto T, Kanazawa K. Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim Biophys Acta 2008; 1780: 743-749
119. Liu CL, Huang YS, Hosokawa M, Miyashita K, Hu ML. Inhibition of proliferation of a hepatoma cell line by fucoxanthin in relation to cell cycle arrest and enhanced gap junctional intercellular communication. Chem Biol Interact 2009; 182: 165-172
120. Park YO, Hwang ES, Moon TW. The effect of lycopene on cell growth and oxidative DNA damage of Hep3B human hepatoma cells. Biofactors 2005; 23: 129-139
121. Hwang ES, Lee HJ. Inhibitory effects of lycopene on the adhesion, invasion, and migration of SK- Hep1 human hepatoma cells. Exp Biol Med (Maywood) 2006; 231: 322-327
122. Huang CS, Fan YE, Lin CY, Hu ML. Lycopene inhibits matrix metalloproteinase- 9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1. J Nutr Biochem 2007; 18: 449-456
123. Chen W, Hou J, Yin Y, Jang J, Zheng Z, Fan H, Zou G. alpha-Bisabolol induces dose- and time-dependent apoptosis in HepG2 cells via a Fas- and mitochondrial-related pathway, involves p53 and NFkappaB. Biochem Pharmacol 2010; 80: 247-254
124. Hsu YL, Wu LY, Kuo PL. Dehydrocostuslactone, a medicinal plant-derived sesquiterpene lactone, induces apoptosis coupled to endoplasmic reticulum stress in liver cancer cells. J Pharmacol Exp Ther 2009; 329: 808-819
125. Xiao Y, Yang FQ, Li SP, Gao JL, Hu G, Lao SC, Conceição EL, Fung KP, Wangl YT, Lee SM. Furanodiene induces G2/ M cell cycle arrest and apoptosis through MAPK signaling and mitochondria-caspase pathway in human hepatocellular carcinoma cells. Cancer Biol Ther 2007; 6: 1044-1050
126. Miao R, Wei J, Zhang Q, Sajja V, Yang J, Wang Q. Redifferentiation of human hepatoma cells (SMMC-7721) induced by two new highly oxygenated bisabolane-type sesquiterpenes. J Biosci 2008; 33: 723-730
127. Sakinah SA, Handayani ST, Hawariah LP. Zerumbone induced apoptosis in liver cancer cells via modulation of Bax/ Bcl- 2 ratio. Cancer Cell Int 2007; 7: 4
128. Sakata K, Hara A, Hirose Y, Yamada Y, Kuno T, Katayama M, Yoshida K, Zheng Q, Murakami A, Ohigashi H, Ikemoto K, Koshimizu K, Tanaka T, Mori H. Dietary supplementation of the citrus antioxidant auraptene inhibits N,N-diethylnitrosamine- induced rat hepatocarcinogenesis. Oncology 2004; 66: 244-252
129. Ong TP, Heidor R, de Conti A, Dagli ML, Moreno FS. Farnesol and geraniol chemopreventive activities during the initial phases of hepatocarcinogenesis involve similar actions on cell proliferation and DNA damage, but distinct actions on apoptosis, plasma cholesterol and HMGCoA reductase. Carcinogenesis 2006; 27: 1194-1203
130. Cardozo MT, de Conti A, Ong TP, Scolastici C, Purgatto E, Horst MA, Bassoli BK, Moreno FS. Chemopreventive effects of β-ionone and geraniol during rat hepatocarcinogenesis promotion: distinct actions on cell proliferation, apoptosis, HMGCoA reductase, and RhoA. J Nutr Biochem 2011; 22: 130-135
131. Hirose M, Hasegawa R, Kimura J, Akagi K, Yoshida Y, Tanaka H, Miki T, Satoh T, Wakabayashi K, Ito N. Inhibitory effects of 1-O-hexyl-2,3,5-trimethylhydroquinone (HTHQ), green tea catechins and other antioxidants on 2-amino-6- methyldipyrido[1,2-a: 3',2'-d]imidazole (Glu-P-1)-induced rat hepatocarcinogenesis and dose-dependent inhibition by HTHQ of lesion induction by Glu-P- 1 or 2-amino-3,8- dimethylimidazo[4,5-f]quinoxaline (MeIQx). Carcinogenesis 1995; 16: 3049-3055
132. Giri RK, Parija T, Das BR. d-limonene chemoprevention of hepatocarcinogenesis in AKR mice: inhibition of c-jun and c-myc. Oncol Rep 1999; 6: 1123-1127
133. Parija T, Das BR. Involvement of YY1 and its correlation with c-myc in NDEA induced hepatocarcinogenesis, its prevention by d-limonene. Mol Biol Rep 2003; 30: 41-46
134. Kaji I, Tatsuta M, Iishi H, Baba M, Inoue A, Kasugai H. Inhibition by d-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve p21(ras) plasma membrane association. Int J Cancer 2001; 93: 441-444
135. Bodake HB, Panicker KN, Kailaje VV, Rao KV. Chemopreventive effect of orange oil on the development of hepatic preneoplastic lesions induced by N-nitrosodiethylamine in rats: an ultrastructural study. Indian J Exp Biol 2002; 40: 245-251
136. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res 1995; 55: 979-983
137. Trivedi NP, Rawal UM, Patel BP. Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integr Cancer Ther 2007; 6: 271-280
138. Trivedi NP, Rawal UM, Patel BP. Potency of andrographolide as an antitumor compound in BHC-induced liver damage. Integr Cancer Ther 2009; 8: 177-189
139. Dhanasekaran M, Baskar AA, Ignacimuthu S, Agastian P, Duraipandiyan V. Chemopreventive potential of Epoxy clerodane diterpene from Tinospora cordifolia against diethylnitrosamine- induced hepatocellular carcinoma. Invest New Drugs 2009; 27: 347-355
140. de Moura Espíndola R, Mazzantini RP, Ong TP, de Conti A, Heidor R, Moreno FS. Geranylgeraniol and beta-ionone inhibit hepatic preneoplastic lesions, cell proliferation, total plasma cholesterol and DNA damage during the initial phases of hepatocarcinogenesis, but only the former inhibits NF-kappaB activation. Carcinogenesis 2005; 26: 1091-1099
141. Janani P, Sivakumari K, Geetha A, Ravisankar B, Parthasarathy C. Chemopreventive effect of bacoside A on N-nitrosodiethylamine- induced hepatocarcinogenesis in rats. J Cancer Res Clin Oncol 2010; 136: 759-770
142. Janani P, Sivakumari K, Geetha A, Yuvaraj S, Parthasarathy C. Bacoside A downregulates matrix metalloproteinases 2 and 9 in DEN-induced hepatocellular carcinoma. Cell Biochem Funct 2010; 28: 164-169
143. Hu DN, Ritch R. Tissue culture of adult human retinal ganglion cells. J Glaucoma 1997; 6: 37-43
144. Slifman NR, Obermeyer WR, Aloi BK, Musser SM, Correll WA, Cichowicz SM, Betz JM, Love LA. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med 1998; 339: 806-811
145. Abdel-Wahhab MA, Hassan NS, El-Kady AA, Khadrawy YA, El-Nekeety AA, Mohamed SR, Sharaf HA, Mannaa FA. Red ginseng extract protects against aflatoxin B1 and fumonisins- induced hepatic pre-cancerous lesions in rats. Food Chem Toxicol 2010; 48: 733-742
146. Shiota G, Harada K, Ishida M, Tomie Y, Okubo M, Katayama S, Ito H, Kawasaki H. Inhibition of hepatocellular carcinoma by glycyrrhizin in diethylnitrosamine-treated mice. Carcinogenesis 1999; 20: 59-63
147. Wan XY, Luo M, Li XD, He P. Hepatoprotective and antihepatocarcinogenic effects of glycyrrhizin and matrine. Chem Biol Interact 2009; 181: 15-19
148. Karim R, Iwai S, Morimura K, Wanibuchi H, Tanaka R, Matsunaga S, Yoshitake A, Fukushima S. Lack of modification of rat hepatocarcinogenesis by fernane-type triterpenoids, isolated from a Euphorbia genus. Teratog Carcinog Mutagen 2002; 22: 293-299
149. Scolastici C, Ong TP, Moreno FS. Squalene does not exhibit a chemopreventive activity and increases plasma cholesterol in a Wistar rat hepatocarcinogenesis model. Nutr Cancer 2004; 50: 101-109
150. Gayathri R, Priya DK, Gunassekaran GR, Sakthisekaran D. Ursolic acid attenuates oxidative stress-mediated hepatocellular carcinoma induction by diethylnitrosamine in male Wistar rats. Asian Pac J Cancer Prev 2009; 10: 933-938
151. Murakoshi M, Nishino H, Satomi Y, Takayasu J, Hasegawa T, Tokuda H, Iwashima A, Okuzumi J, Okabe H, Kitano H. Potent preventive action of alpha-carotene against carcinogenesis: spontaneous liver carcinogenesis and promoting stage of lung and skin carcinogenesis in mice are suppressed more effectively by alpha-carotene than by beta-carotene. Cancer Res 1992; 52: 6583-6587
152. Tsuda H, Iwahori Y, Asamoto M, Baba-Toriyama H, Hori T, Kim DJ, Uehara N, Iigo M, Takasuka N, Murakoshi M, Nishino H, Kakizoe T, Araki E, Yazawa K. Demonstration of organotropic effects of chemopreventive agents in multiorgan carcinogenesis models. IARC Sci Publ 1996; 143-150
153. Astorg P, Gradelet S, Bergès R, Suschetet M. No evidence for an inhibitory effect of beta-carotene or of canthaxanthin on the initiation of liver preneoplastic foci by diethylnitrosamine in the rat. Nutr Cancer 1996; 25: 27-34
154. Astorg P, Gradelet S, Bergès R, Suschetet M. Dietary lycopene decreases the initiation of liver preneoplastic foci by diethylnitrosamine in the rat. Nutr Cancer 1997; 29: 60-68
155. Tharappel JC, Lehmler HJ, Srinivasan C, Robertson LW, Spear BT, Glauert HP. Effect of antioxidant phytochemicals on the hepatic tumor promoting activity of 3,3',4,4'-tetrachlorobiphenyl (PCB-77). Food Chem Toxicol 2008; 46: 3467-3474
156. Moreno FS, Rizzi MB, Dagli ML, Penteado MV. Inhibitory effects of beta-carotene on preneoplastic lesions induced in Wistar rats by the resistant hepatocyte model. Carcinogenesis 1991; 12: 1817-1822
157. Moreno FS, Wu TS, Penteado MV, Rizzi MB, Jordão Júnior AA, Almeida-Muradian LB, Dagli ML. A comparison of beta- carotene and vitamin A effects on a hepatocarcinogenesis model. Int J Vitam Nutr Res 1995; 65: 87-94
158. Rizzi MB, Dagli ML, Jordão AA, Penteado MV, Moreno FS. beta-carotene inhibits persistent and stimulates remodeling gamma GT-positive preneoplastic lesions during early promotion of hepatocarcinogenesis. Int J Vitam Nutr Res 1997; 67: 415-422
159. Farber E. Similarities in the sequence of early histological changes induced in the liver of the rat by ethionine, 2-acetylamino- fluorene, and 3'-methyl-4-dimethylaminoazobenzene. Cancer Res 1956; 16: 142-148
160. Dagli ML, Guerra JL, Sinhorini IL, Wu TS, Rizzi MB, Penteado MV, Moreno FS. Beta-carotene reduces the ductular (oval) cell reaction in the liver of Wistar rats submitted to the resistant hepatocyte model of carcinogenesis. Pathology 1998; 30: 259-266
161. Moreno FS, S-Wu T, Naves MM, Silveira ER, Oloris SC, da Costa MA, Dagli ML, Ong TP. Inhibitory effects of beta-carotene and vitamin a during the progression phase of hepatocarcinogenesis involve inhibition of cell proliferation but not alterations in DNA methylation. Nutr Cancer 2002; 44: 80-88
162. Ambrogi F, Biganzoli E, Boracchi P. Multiple correspondence analysis in S-PLUS. Comput Methods Programs Biomed 2005; 79: 161-167
163. Sampaio AR, Chagas CE, Ong TP, Moreno FS. Vitamin A and beta-carotene inhibitory effect during 1,2-dimethylhydrazine induced hepatocarcinogenesis potentiated by 5-azacytidine. Food Chem Toxicol 2007; 45: 563-567
164. Sarkar A, Mukherjee B, Chatterjee M. Inhibitory effect of beta-carotene on chronic 2-acetylaminofluorene induced hepatocarcinogenesis in rat: reflection in hepatic drug metabolism. Carcinogenesis 1994; 15: 1055-1060
165. Sarkar A, Mukherjee B, Chatterjee M. Inhibition of 3'-methyl- 4-dimethylaminoazobenzene-induced hepatocarcinogenesis in rat by dietary beta-carotene: changes in hepatic antioxidant defense enzyme levels. Int J Cancer 1995; 61: 799-805
166. Sarkar A, Bishayee A, Chatterjee M. Beta-carotene prevents lipid peroxidation and red blood cell membrane protein damage in experimental hepatocarcinogenesis. Cancer Biochem Biophys 1995; 15: 111-125
167. Sarkar A, Basak R, Bishayee A, Basak J, Chatterjee M. Betacarotene inhibits rat liver chromosomal aberrations and DNA chain break after a single injection of diethylnitrosamine. Br J Cancer 1997; 76: 855-861
168. Bishayee A, Sarkar A, Chatterjee M. Further evidence for chemopreventive potential of beta-carotene against experimental carcinogenesis: diethylnitrosamine-initiated and phenobarbital-promoted hepatocarcinogenesis is prevented more effectively by beta-carotene than by retinoic acid. Nutr Cancer 2000; 37: 89-98
169. Tsuda H, Uehara N, Iwahori Y, Asamoto M, Iigo M, Nagao M, Matsumoto K, Ito M, Hirono I. Chemopreventive effects of beta-carotene, alpha-tocopherol and five naturally occurring antioxidants on initiation of hepatocarcinogenesis by 2-amino-3-methylimidazo[4,5-f]quinoline in the rat. Jpn J Cancer Res 1994; 85: 1214-1219
170. Ogawa T, Higashi S, Kawarada Y, Mizumoto R. Role of reactive oxygen in synthetic estrogen induction of hepatocellularcarcinomas in rats and preventive effect of vitamins. Carcinogenesis 1995; 16: 831-836
171. Uehara N, Iwahori Y, Asamoto M, Baba-Toriyama H, Iigo M, Ochiai M, Nagao M, Nakayama M, Degawa M, Matsumoto K, Hirono I, Beppu H, Fujita K, Tsuda H. Decreased levels of 2-amino-3-methylimidazo[4,5-f]quinoline-DNA adducts in rats treated with beta-carotene, alpha-tocopherol and freezedried aloe. Jpn J Cancer Res 1996; 87: 342-348
172. Gradelet S, Astorg P, Le Bon AM, Bergès R, Suschetet M. Modulation of aflatoxin B1 carcinogenicity, genotoxicity and metabolism in rat liver by dietary carotenoids: evidence for a protective effect of CYP1A inducers. Cancer Lett 1997; 114: 221-223
173. Gradelet S, Le Bon AM, Bergès R, Suschetet M, Astorg P. Dietary carotenoids inhibit aflatoxin B1-induced liver preneoplastic foci and DNA damage in the rat: role of the modulation of aflatoxin B1 metabolism. Carcinogenesis 1998; 19: 403-411
174. Sadek IA, Hayat LG. Initiation and post-initiation chemopreventive effects of beta-carotene in toad liver carcinogenesis. Histol Histopathol 1996; 11: 357-360
175. Chattopadhyay MB, C B MK, Kanna PS, Ray RS, Roy S, Chatterjee M. Combined supplementation of vanadium and beta-carotene suppresses placental glutathione S-transferasepositive foci and enhances antioxidant functions during the inhibition of diethylnitrosamine-induced rat liver carcinogenesis. J Gastroenterol Hepatol 2004; 19: 683-693
176. Chattopadhyay MB, Mukherjee S, Kulkarni I, Vijayan V, Doloi M, Kanjilal N, Chatterjee M. Proton-Induced X-ray Emission (PIXE) Analysis and DNA-chain Break study in rat hepatocarcinogenesis: A possible chemopreventive role by combined supplementation of vanadium and beta-carotene. Cancer Cell Int 2005; 5: 16
177. Bishayee A, Waghray A, Patel MA, Chatterjee M. Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence. Cancer Lett 2010; 294: 1-12
178. Singletary K. Diet, natural products and cancer chemoprevention. J Nutr 2000; 130: 465S-466S
179. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004; 229: 567-585
180. Ohizumi H, Masuda Y, Nakajo S, Sakai I, Ohsawa S, Nakaya K. Geranylgeraniol is a potent inducer of apoptosis in tumor cells. J Biochem 1995; 117: 11-13
181. Toledo LP, Ong TP, Pinho AL, Jordão A, Vanucchi H, Moreno FS. Inhibitory effects of lutein and lycopene on placental glutathione S-transferase-positive preneoplastic lesions and DNA strand breakage induced in Wistar rats by the resistant hepatocyte model of hepatocarcinogenesis. Nutr Cancer 2003; 47: 62-69
182. Moreno FS, Toledo LP, de Conti A, Heidor R, Jordão A, Vannucchi H, Cardozo MT, Ong TP. Lutein presents suppressing but not blocking chemopreventive activity during diethylnitrosamine-induced hepatocarcinogenesis and this involves inhibition of DNA damage. Chem Biol Interact 2007; 168: 221-228
183. Watanabe S, Kitade Y, Masaki T, Nishioka M, Satoh K, Nishino H. Effects of lycopene and Sho-saiko-to on hepatocarcinogenesis in a rat model of spontaneous liver cancer. Nutr Cancer 2001; 39: 96-101
184. Wang Y, Ausman LM, Greenberg AS, Russell RM, Wang XD. Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitis-promoted hepatocarcinogenesis in rats. Int J Cancer 2010; 126: 1788-1796
185. McAnally JA, Jung M, Mo H. Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells. Cancer Lett 2003; 202: 181-192
186. Taha MM, Abdul AB, Abdullah R, Ibrahim TA, Abdelwahab SI, Mohan S. Potential chemoprevention of diethylnitrosamine- initiated and 2-acetylaminofluorene-promoted hepatocarcinogenesis by zerumbone from the rhizomes of the subtropical ginger (Zingiber zerumbet). Chem Biol Interact 2010; 186: 295-305
187. Liu RH. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 2004; 134: 3479S-3485S
188. Lansky EP. Beware of pomegranates bearing 40% ellagic Acid. J Med Food 2006; 9: 119-122
189. de Kok TM, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds: a review. Eur J Nutr 2008; 47 Suppl 2: 51-59
190. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila) 2009; 2: 514-517
191. Korkina LG, De Luca C, Kostyuk VA, Pastore S. Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr Med Chem 2009; 16: 3943-3965
192. Guo M, Zhang S, Song F, Wang D, Liu Z, Liu S. Studies on the non-covalent complexes between oleanolic acid and cyclodextrins using electrospray ionization tandem mass spectrometry. J Mass Spectrom 2003; 38: 723-731
193. Chen Y, Liu J, Yang X, Zhao X, Xu H. Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect. J Pharm Pharmacol 2005; 57: 259-264
194. Kang HS, Park JE, Lee YJ, Chang IS, Chung YI, Tae G. Preparation of liposomes containing oleanolic acid via micelle-tovesicle transition. J Nanosci Nanotechnol 2007; 7: 3944-3948